

Global Acute Myeloid Leukemia Drugs Market Growth 2024-2030

https://marketpublishers.com/r/G79B5AC086BEN.html

Date: March 2024 Pages: 115 Price: US\$ 3,660.00 (Single User License) ID: G79B5AC086BEN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

According to our LPI (LP Information) latest study, the global Acute Myeloid Leukemia Drugs market size was valued at US\$ 1719.8 million in 2023. With growing demand in downstream market, the Acute Myeloid Leukemia Drugs is forecast to a readjusted size of US\$ 3477.3 million by 2030 with a CAGR of 10.6% during review period.

The research report highlights the growth potential of the global Acute Myeloid Leukemia Drugs market. Acute Myeloid Leukemia Drugs are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Acute Myeloid Leukemia Drugs. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Acute Myeloid Leukemia Drugs market.

Acute myeloid leukemia is the second frequent type (after acute lymphocytic leukemia) of leukemia diagnosed in infants. About 15% of children from birth to 19 years of age diagnosed with leukemia have acute myeloid leukemia. The risk of acute myeloid leukemia is closely associated with age. About 90% of acute myeloid leukemia is diagnosed in middle age.

The Acute Myeloid Leukemia (AML) Drugs market driver is the increasing incidence of AML globally, leading to a growing demand for effective treatments. The introduction of novel targeted therapies and immunotherapies has also driven market growth. However, challenges include the complexity of AML genetics, the need for personalized



treatment approaches, and the high cost of newer therapies. Additionally, the competitive landscape and stringent regulatory requirements pose challenges for market players. Despite challenges, the AML Drugs market presents potential for growth as researchers and pharmaceutical companies continue to explore innovative treatments for this aggressive hematologic malignancy.

Key Features:

The report on Acute Myeloid Leukemia Drugs market reflects various aspects and provide valuable insights into the industry.

Market Size and Growth: The research report provide an overview of the current size and growth of the Acute Myeloid Leukemia Drugs market. It may include historical data, market segmentation by Type (e.g., Chemotherapy, Targeted Therapy), and regional breakdowns.

Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Acute Myeloid Leukemia Drugs market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.

Competitive Landscape: The research report provides analysis of the competitive landscape within the Acute Myeloid Leukemia Drugs market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.

Technological Developments: The research report can delve into the latest technological developments in the Acute Myeloid Leukemia Drugs industry. This include advancements in Acute Myeloid Leukemia Drugs technology, Acute Myeloid Leukemia Drugs new entrants, Acute Myeloid Leukemia Drugs new investment, and other innovations that are shaping the future of Acute Myeloid Leukemia Drugs.

Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Acute Myeloid Leukemia Drugs market. It includes factors influencing customer ' purchasing decisions, preferences for Acute Myeloid Leukemia Drugs product.

Government Policies and Incentives: The research report analyse the impact of



government policies and incentives on the Acute Myeloid Leukemia Drugs market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Acute Myeloid Leukemia Drugs market. The report also evaluates the effectiveness of these policies in driving market growth.

Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Acute Myeloid Leukemia Drugs market.

Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Acute Myeloid Leukemia Drugs industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.

Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Acute Myeloid Leukemia Drugs market.

Market Segmentation:

Acute Myeloid Leukemia Drugs market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.

Segmentation by type

Chemotherapy

Targeted Therapy

Other

Segmentation by application

Hospital

Clinic



Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy



Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Ambit Biosciences Corporation Bristol Myers Squibb Cephalon Clavis Pharma Eisai Genzyme Corporation Sunesis Pharmaceuticals Novartis Eli Lilly and Company

Otsuka Holdings



Takeda Pharmaceuticals

Key Questions Addressed in this Report

What is the 10-year outlook for the global Acute Myeloid Leukemia Drugs market?

What factors are driving Acute Myeloid Leukemia Drugs market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Acute Myeloid Leukemia Drugs market opportunities vary by end market size?

How does Acute Myeloid Leukemia Drugs break out type, application?



Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
- 2.1.1 Global Acute Myeloid Leukemia Drugs Annual Sales 2019-2030
- 2.1.2 World Current & Future Analysis for Acute Myeloid Leukemia Drugs by Geographic Region, 2019, 2023 & 2030
- 2.1.3 World Current & Future Analysis for Acute Myeloid Leukemia Drugs by Country/Region, 2019, 2023 & 2030
- 2.2 Acute Myeloid Leukemia Drugs Segment by Type
 - 2.2.1 Chemotherapy
 - 2.2.2 Targeted Therapy
 - 2.2.3 Other
- 2.3 Acute Myeloid Leukemia Drugs Sales by Type
 - 2.3.1 Global Acute Myeloid Leukemia Drugs Sales Market Share by Type (2019-2024)
- 2.3.2 Global Acute Myeloid Leukemia Drugs Revenue and Market Share by Type (2019-2024)
- 2.3.3 Global Acute Myeloid Leukemia Drugs Sale Price by Type (2019-2024)
- 2.4 Acute Myeloid Leukemia Drugs Segment by Application
 - 2.4.1 Hospital
 - 2.4.2 Clinic
 - 2.4.3 Others
- 2.5 Acute Myeloid Leukemia Drugs Sales by Application
- 2.5.1 Global Acute Myeloid Leukemia Drugs Sale Market Share by Application (2019-2024)
- 2.5.2 Global Acute Myeloid Leukemia Drugs Revenue and Market Share by Application (2019-2024)



2.5.3 Global Acute Myeloid Leukemia Drugs Sale Price by Application (2019-2024)

3 GLOBAL ACUTE MYELOID LEUKEMIA DRUGS BY COMPANY

- 3.1 Global Acute Myeloid Leukemia Drugs Breakdown Data by Company
- 3.1.1 Global Acute Myeloid Leukemia Drugs Annual Sales by Company (2019-2024)
- 3.1.2 Global Acute Myeloid Leukemia Drugs Sales Market Share by Company (2019-2024)
- 3.2 Global Acute Myeloid Leukemia Drugs Annual Revenue by Company (2019-2024)
- 3.2.1 Global Acute Myeloid Leukemia Drugs Revenue by Company (2019-2024)

3.2.2 Global Acute Myeloid Leukemia Drugs Revenue Market Share by Company (2019-2024)

3.3 Global Acute Myeloid Leukemia Drugs Sale Price by Company

3.4 Key Manufacturers Acute Myeloid Leukemia Drugs Producing Area Distribution, Sales Area, Product Type

- 3.4.1 Key Manufacturers Acute Myeloid Leukemia Drugs Product Location Distribution
- 3.4.2 Players Acute Myeloid Leukemia Drugs Products Offered
- 3.5 Market Concentration Rate Analysis
- 3.5.1 Competition Landscape Analysis
- 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
- 3.6 New Products and Potential Entrants
- 3.7 Mergers & Acquisitions, Expansion

4 WORLD HISTORIC REVIEW FOR ACUTE MYELOID LEUKEMIA DRUGS BY GEOGRAPHIC REGION

4.1 World Historic Acute Myeloid Leukemia Drugs Market Size by Geographic Region (2019-2024)

4.1.1 Global Acute Myeloid Leukemia Drugs Annual Sales by Geographic Region (2019-2024)

4.1.2 Global Acute Myeloid Leukemia Drugs Annual Revenue by Geographic Region (2019-2024)

4.2 World Historic Acute Myeloid Leukemia Drugs Market Size by Country/Region (2019-2024)

4.2.1 Global Acute Myeloid Leukemia Drugs Annual Sales by Country/Region (2019-2024)

4.2.2 Global Acute Myeloid Leukemia Drugs Annual Revenue by Country/Region (2019-2024)

4.3 Americas Acute Myeloid Leukemia Drugs Sales Growth



- 4.4 APAC Acute Myeloid Leukemia Drugs Sales Growth
- 4.5 Europe Acute Myeloid Leukemia Drugs Sales Growth
- 4.6 Middle East & Africa Acute Myeloid Leukemia Drugs Sales Growth

5 AMERICAS

- 5.1 Americas Acute Myeloid Leukemia Drugs Sales by Country
- 5.1.1 Americas Acute Myeloid Leukemia Drugs Sales by Country (2019-2024)
- 5.1.2 Americas Acute Myeloid Leukemia Drugs Revenue by Country (2019-2024)
- 5.2 Americas Acute Myeloid Leukemia Drugs Sales by Type
- 5.3 Americas Acute Myeloid Leukemia Drugs Sales by Application
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil

6 APAC

- 6.1 APAC Acute Myeloid Leukemia Drugs Sales by Region
- 6.1.1 APAC Acute Myeloid Leukemia Drugs Sales by Region (2019-2024)
- 6.1.2 APAC Acute Myeloid Leukemia Drugs Revenue by Region (2019-2024)
- 6.2 APAC Acute Myeloid Leukemia Drugs Sales by Type
- 6.3 APAC Acute Myeloid Leukemia Drugs Sales by Application
- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 China Taiwan

7 EUROPE

- 7.1 Europe Acute Myeloid Leukemia Drugs by Country
- 7.1.1 Europe Acute Myeloid Leukemia Drugs Sales by Country (2019-2024)
- 7.1.2 Europe Acute Myeloid Leukemia Drugs Revenue by Country (2019-2024)
- 7.2 Europe Acute Myeloid Leukemia Drugs Sales by Type
- 7.3 Europe Acute Myeloid Leukemia Drugs Sales by Application
- 7.4 Germany



7.5 France7.6 UK7.7 Italy7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Acute Myeloid Leukemia Drugs by Country
8.1.1 Middle East & Africa Acute Myeloid Leukemia Drugs Sales by Country
(2019-2024)
8.1.2 Middle East & Africa Acute Myeloid Leukemia Drugs Revenue by Country
(2019-2024)
8.2 Middle East & Africa Acute Myeloid Leukemia Drugs Sales by Type
8.3 Middle East & Africa Acute Myeloid Leukemia Drugs Sales by Application
8.4 Egypt
8.5 South Africa

- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

- 10.1 Raw Material and Suppliers
- 10.2 Manufacturing Cost Structure Analysis of Acute Myeloid Leukemia Drugs
- 10.3 Manufacturing Process Analysis of Acute Myeloid Leukemia Drugs
- 10.4 Industry Chain Structure of Acute Myeloid Leukemia Drugs

11 MARKETING, DISTRIBUTORS AND CUSTOMER

- 11.1 Sales Channel
 - 11.1.1 Direct Channels
 - 11.1.2 Indirect Channels
- 11.2 Acute Myeloid Leukemia Drugs Distributors



11.3 Acute Myeloid Leukemia Drugs Customer

12 WORLD FORECAST REVIEW FOR ACUTE MYELOID LEUKEMIA DRUGS BY GEOGRAPHIC REGION

12.1 Global Acute Myeloid Leukemia Drugs Market Size Forecast by Region

12.1.1 Global Acute Myeloid Leukemia Drugs Forecast by Region (2025-2030)

12.1.2 Global Acute Myeloid Leukemia Drugs Annual Revenue Forecast by Region (2025-2030)

- 12.2 Americas Forecast by Country
- 12.3 APAC Forecast by Region
- 12.4 Europe Forecast by Country
- 12.5 Middle East & Africa Forecast by Country
- 12.6 Global Acute Myeloid Leukemia Drugs Forecast by Type
- 12.7 Global Acute Myeloid Leukemia Drugs Forecast by Application

13 KEY PLAYERS ANALYSIS

- 13.1 Ambit Biosciences Corporation
 - 13.1.1 Ambit Biosciences Corporation Company Information
- 13.1.2 Ambit Biosciences Corporation Acute Myeloid Leukemia Drugs Product
- Portfolios and Specifications

13.1.3 Ambit Biosciences Corporation Acute Myeloid Leukemia Drugs Sales, Revenue, Price and Gross Margin (2019-2024)

- 13.1.4 Ambit Biosciences Corporation Main Business Overview
- 13.1.5 Ambit Biosciences Corporation Latest Developments

13.2 Bristol Myers Squibb

13.2.1 Bristol Myers Squibb Company Information

13.2.2 Bristol Myers Squibb Acute Myeloid Leukemia Drugs Product Portfolios and Specifications

13.2.3 Bristol Myers Squibb Acute Myeloid Leukemia Drugs Sales, Revenue, Price and Gross Margin (2019-2024)

- 13.2.4 Bristol Myers Squibb Main Business Overview
- 13.2.5 Bristol Myers Squibb Latest Developments

13.3 Cephalon

- 13.3.1 Cephalon Company Information
- 13.3.2 Cephalon Acute Myeloid Leukemia Drugs Product Portfolios and Specifications

13.3.3 Cephalon Acute Myeloid Leukemia Drugs Sales, Revenue, Price and Gross Margin (2019-2024)



13.3.4 Cephalon Main Business Overview

13.3.5 Cephalon Latest Developments

13.4 Clavis Pharma

13.4.1 Clavis Pharma Company Information

13.4.2 Clavis Pharma Acute Myeloid Leukemia Drugs Product Portfolios and

Specifications

13.4.3 Clavis Pharma Acute Myeloid Leukemia Drugs Sales, Revenue, Price and Gross Margin (2019-2024)

13.4.4 Clavis Pharma Main Business Overview

13.4.5 Clavis Pharma Latest Developments

13.5 Eisai

13.5.1 Eisai Company Information

13.5.2 Eisai Acute Myeloid Leukemia Drugs Product Portfolios and Specifications

13.5.3 Eisai Acute Myeloid Leukemia Drugs Sales, Revenue, Price and Gross Margin (2019-2024)

13.5.4 Eisai Main Business Overview

13.5.5 Eisai Latest Developments

13.6 Genzyme Corporation

13.6.1 Genzyme Corporation Company Information

13.6.2 Genzyme Corporation Acute Myeloid Leukemia Drugs Product Portfolios and Specifications

13.6.3 Genzyme Corporation Acute Myeloid Leukemia Drugs Sales, Revenue, Price and Gross Margin (2019-2024)

13.6.4 Genzyme Corporation Main Business Overview

13.6.5 Genzyme Corporation Latest Developments

13.7 Sunesis Pharmaceuticals

13.7.1 Sunesis Pharmaceuticals Company Information

13.7.2 Sunesis Pharmaceuticals Acute Myeloid Leukemia Drugs Product Portfolios and Specifications

13.7.3 Sunesis Pharmaceuticals Acute Myeloid Leukemia Drugs Sales, Revenue, Price and Gross Margin (2019-2024)

13.7.4 Sunesis Pharmaceuticals Main Business Overview

13.7.5 Sunesis Pharmaceuticals Latest Developments

13.8 Novartis

13.8.1 Novartis Company Information

13.8.2 Novartis Acute Myeloid Leukemia Drugs Product Portfolios and Specifications

13.8.3 Novartis Acute Myeloid Leukemia Drugs Sales, Revenue, Price and Gross Margin (2019-2024)

13.8.4 Novartis Main Business Overview





13.8.5 Novartis Latest Developments

13.9 Eli Lilly and Company

13.9.1 Eli Lilly and Company Company Information

13.9.2 Eli Lilly and Company Acute Myeloid Leukemia Drugs Product Portfolios and Specifications

13.9.3 Eli Lilly and Company Acute Myeloid Leukemia Drugs Sales, Revenue, Price and Gross Margin (2019-2024)

13.9.4 Eli Lilly and Company Main Business Overview

13.9.5 Eli Lilly and Company Latest Developments

13.10 Otsuka Holdings

13.10.1 Otsuka Holdings Company Information

13.10.2 Otsuka Holdings Acute Myeloid Leukemia Drugs Product Portfolios and Specifications

13.10.3 Otsuka Holdings Acute Myeloid Leukemia Drugs Sales, Revenue, Price and Gross Margin (2019-2024)

13.10.4 Otsuka Holdings Main Business Overview

13.10.5 Otsuka Holdings Latest Developments

13.11 Takeda Pharmaceuticals

13.11.1 Takeda Pharmaceuticals Company Information

13.11.2 Takeda Pharmaceuticals Acute Myeloid Leukemia Drugs Product Portfolios and Specifications

13.11.3 Takeda Pharmaceuticals Acute Myeloid Leukemia Drugs Sales, Revenue, Price and Gross Margin (2019-2024)

13.11.4 Takeda Pharmaceuticals Main Business Overview

13.11.5 Takeda Pharmaceuticals Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION



List Of Tables

LIST OF TABLES

Table 1. Acute Myeloid Leukemia Drugs Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & (\$ millions) Table 2. Acute Myeloid Leukemia Drugs Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & (\$ millions) Table 3. Major Players of Chemotherapy Table 4. Major Players of Targeted Therapy Table 5. Major Players of Other Table 6. Global Acute Myeloid Leukemia Drugs Sales by Type (2019-2024) & (K Units) Table 7. Global Acute Myeloid Leukemia Drugs Sales Market Share by Type (2019-2024)Table 8. Global Acute Myeloid Leukemia Drugs Revenue by Type (2019-2024) & (\$ million) Table 9. Global Acute Myeloid Leukemia Drugs Revenue Market Share by Type (2019-2024)Table 10. Global Acute Myeloid Leukemia Drugs Sale Price by Type (2019-2024) & (USD/Unit) Table 11. Global Acute Myeloid Leukemia Drugs Sales by Application (2019-2024) & (K Units) Table 12. Global Acute Myeloid Leukemia Drugs Sales Market Share by Application (2019-2024)Table 13. Global Acute Myeloid Leukemia Drugs Revenue by Application (2019-2024) Table 14. Global Acute Myeloid Leukemia Drugs Revenue Market Share by Application (2019-2024)Table 15. Global Acute Myeloid Leukemia Drugs Sale Price by Application (2019-2024) & (USD/Unit) Table 16. Global Acute Myeloid Leukemia Drugs Sales by Company (2019-2024) & (K Units) Table 17. Global Acute Myeloid Leukemia Drugs Sales Market Share by Company (2019-2024)Table 18. Global Acute Myeloid Leukemia Drugs Revenue by Company (2019-2024) (\$ Millions) Table 19. Global Acute Myeloid Leukemia Drugs Revenue Market Share by Company (2019-2024)Table 20. Global Acute Myeloid Leukemia Drugs Sale Price by Company (2019-2024) & (USD/Unit)



Table 21. Key Manufacturers Acute Myeloid Leukemia Drugs Producing Area Distribution and Sales Area Table 22. Players Acute Myeloid Leukemia Drugs Products Offered Table 23. Acute Myeloid Leukemia Drugs Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)Table 24. New Products and Potential Entrants Table 25. Mergers & Acquisitions, Expansion Table 26. Global Acute Myeloid Leukemia Drugs Sales by Geographic Region (2019-2024) & (K Units) Table 27. Global Acute Myeloid Leukemia Drugs Sales Market Share Geographic Region (2019-2024) Table 28. Global Acute Myeloid Leukemia Drugs Revenue by Geographic Region (2019-2024) & (\$ millions) Table 29. Global Acute Myeloid Leukemia Drugs Revenue Market Share by Geographic Region (2019-2024) Table 30. Global Acute Myeloid Leukemia Drugs Sales by Country/Region (2019-2024) & (K Units) Table 31. Global Acute Myeloid Leukemia Drugs Sales Market Share by Country/Region (2019-2024) Table 32. Global Acute Myeloid Leukemia Drugs Revenue by Country/Region (2019-2024) & (\$ millions) Table 33. Global Acute Myeloid Leukemia Drugs Revenue Market Share by Country/Region (2019-2024) Table 34. Americas Acute Myeloid Leukemia Drugs Sales by Country (2019-2024) & (K Units) Table 35. Americas Acute Myeloid Leukemia Drugs Sales Market Share by Country (2019-2024) Table 36. Americas Acute Myeloid Leukemia Drugs Revenue by Country (2019-2024) & (\$ Millions) Table 37. Americas Acute Myeloid Leukemia Drugs Revenue Market Share by Country (2019-2024)Table 38. Americas Acute Myeloid Leukemia Drugs Sales by Type (2019-2024) & (K Units) Table 39. Americas Acute Myeloid Leukemia Drugs Sales by Application (2019-2024) & (K Units) Table 40. APAC Acute Myeloid Leukemia Drugs Sales by Region (2019-2024) & (K Units) Table 41. APAC Acute Myeloid Leukemia Drugs Sales Market Share by Region (2019-2024)



Table 42. APAC Acute Myeloid Leukemia Drugs Revenue by Region (2019-2024) & (\$ Millions)

Table 43. APAC Acute Myeloid Leukemia Drugs Revenue Market Share by Region (2019-2024)

Table 44. APAC Acute Myeloid Leukemia Drugs Sales by Type (2019-2024) & (K Units) Table 45. APAC Acute Myeloid Leukemia Drugs Sales by Application (2019-2024) & (K Units)

Table 46. Europe Acute Myeloid Leukemia Drugs Sales by Country (2019-2024) & (K Units)

Table 47. Europe Acute Myeloid Leukemia Drugs Sales Market Share by Country (2019-2024)

Table 48. Europe Acute Myeloid Leukemia Drugs Revenue by Country (2019-2024) & (\$ Millions)

Table 49. Europe Acute Myeloid Leukemia Drugs Revenue Market Share by Country (2019-2024)

Table 50. Europe Acute Myeloid Leukemia Drugs Sales by Type (2019-2024) & (K Units)

Table 51. Europe Acute Myeloid Leukemia Drugs Sales by Application (2019-2024) & (K Units)

Table 52. Middle East & Africa Acute Myeloid Leukemia Drugs Sales by Country (2019-2024) & (K Units)

Table 53. Middle East & Africa Acute Myeloid Leukemia Drugs Sales Market Share by Country (2019-2024)

Table 54. Middle East & Africa Acute Myeloid Leukemia Drugs Revenue by Country (2019-2024) & (\$ Millions)

Table 55. Middle East & Africa Acute Myeloid Leukemia Drugs Revenue Market Share by Country (2019-2024)

Table 56. Middle East & Africa Acute Myeloid Leukemia Drugs Sales by Type (2019-2024) & (K Units)

Table 57. Middle East & Africa Acute Myeloid Leukemia Drugs Sales by Application (2019-2024) & (K Units)

- Table 58. Key Market Drivers & Growth Opportunities of Acute Myeloid Leukemia Drugs
- Table 59. Key Market Challenges & Risks of Acute Myeloid Leukemia Drugs
- Table 60. Key Industry Trends of Acute Myeloid Leukemia Drugs
- Table 61. Acute Myeloid Leukemia Drugs Raw Material
- Table 62. Key Suppliers of Raw Materials
- Table 63. Acute Myeloid Leukemia Drugs Distributors List
- Table 64. Acute Myeloid Leukemia Drugs Customer List
- Table 65. Global Acute Myeloid Leukemia Drugs Sales Forecast by Region (2025-2030)



& (K Units)

Table 66. Global Acute Myeloid Leukemia Drugs Revenue Forecast by Region (2025-2030) & (\$ millions)

Table 67. Americas Acute Myeloid Leukemia Drugs Sales Forecast by Country (2025-2030) & (K Units)

Table 68. Americas Acute Myeloid Leukemia Drugs Revenue Forecast by Country (2025-2030) & (\$ millions)

Table 69. APAC Acute Myeloid Leukemia Drugs Sales Forecast by Region (2025-2030) & (K Units)

Table 70. APAC Acute Myeloid Leukemia Drugs Revenue Forecast by Region (2025-2030) & (\$ millions)

Table 71. Europe Acute Myeloid Leukemia Drugs Sales Forecast by Country (2025-2030) & (K Units)

Table 72. Europe Acute Myeloid Leukemia Drugs Revenue Forecast by Country(2025-2030) & (\$ millions)

Table 73. Middle East & Africa Acute Myeloid Leukemia Drugs Sales Forecast by Country (2025-2030) & (K Units)

Table 74. Middle East & Africa Acute Myeloid Leukemia Drugs Revenue Forecast by Country (2025-2030) & (\$ millions)

Table 75. Global Acute Myeloid Leukemia Drugs Sales Forecast by Type (2025-2030) & (K Units)

Table 76. Global Acute Myeloid Leukemia Drugs Revenue Forecast by Type (2025-2030) & (\$ Millions)

Table 77. Global Acute Myeloid Leukemia Drugs Sales Forecast by Application (2025-2030) & (K Units)

Table 78. Global Acute Myeloid Leukemia Drugs Revenue Forecast by Application (2025-2030) & (\$ Millions)

Table 79. Ambit Biosciences Corporation Basic Information, Acute Myeloid Leukemia Drugs Manufacturing Base, Sales Area and Its Competitors

Table 80. Ambit Biosciences Corporation Acute Myeloid Leukemia Drugs ProductPortfolios and Specifications

Table 81. Ambit Biosciences Corporation Acute Myeloid Leukemia Drugs Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 82. Ambit Biosciences Corporation Main Business

Table 83. Ambit Biosciences Corporation Latest Developments

Table 84. Bristol Myers Squibb Basic Information, Acute Myeloid Leukemia DrugsManufacturing Base, Sales Area and Its Competitors

Table 85. Bristol Myers Squibb Acute Myeloid Leukemia Drugs Product Portfolios and Specifications



Table 86. Bristol Myers Squibb Acute Myeloid Leukemia Drugs Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2019-2024) Table 87. Bristol Myers Squibb Main Business Table 88. Bristol Myers Squibb Latest Developments Table 89. Cephalon Basic Information, Acute Myeloid Leukemia Drugs Manufacturing Base, Sales Area and Its Competitors Table 90. Cephalon Acute Myeloid Leukemia Drugs Product Portfolios and **Specifications** Table 91. Cephalon Acute Myeloid Leukemia Drugs Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2019-2024) Table 92. Cephalon Main Business Table 93. Cephalon Latest Developments Table 94. Clavis Pharma Basic Information, Acute Myeloid Leukemia Drugs Manufacturing Base, Sales Area and Its Competitors Table 95. Clavis Pharma Acute Myeloid Leukemia Drugs Product Portfolios and **Specifications** Table 96. Clavis Pharma Acute Myeloid Leukemia Drugs Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2019-2024) Table 97. Clavis Pharma Main Business Table 98. Clavis Pharma Latest Developments Table 99. Eisai Basic Information, Acute Myeloid Leukemia Drugs Manufacturing Base, Sales Area and Its Competitors Table 100. Eisai Acute Myeloid Leukemia Drugs Product Portfolios and Specifications Table 101. Eisai Acute Myeloid Leukemia Drugs Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2019-2024) Table 102. Eisai Main Business Table 103. Eisai Latest Developments Table 104. Genzyme Corporation Basic Information, Acute Myeloid Leukemia Drugs Manufacturing Base, Sales Area and Its Competitors Table 105. Genzyme Corporation Acute Myeloid Leukemia Drugs Product Portfolios and Specifications Table 106. Genzyme Corporation Acute Myeloid Leukemia Drugs Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2019-2024) Table 107. Genzyme Corporation Main Business Table 108. Genzyme Corporation Latest Developments Table 109. Sunesis Pharmaceuticals Basic Information, Acute Myeloid Leukemia Drugs Manufacturing Base, Sales Area and Its Competitors Table 110. Sunesis Pharmaceuticals Acute Myeloid Leukemia Drugs Product Portfolios and Specifications



Table 111. Sunesis Pharmaceuticals Acute Myeloid Leukemia Drugs Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2019-2024) Table 112. Sunesis Pharmaceuticals Main Business Table 113. Sunesis Pharmaceuticals Latest Developments Table 114. Novartis Basic Information, Acute Myeloid Leukemia Drugs Manufacturing Base, Sales Area and Its Competitors Table 115. Novartis Acute Myeloid Leukemia Drugs Product Portfolios and **Specifications** Table 116. Novartis Acute Myeloid Leukemia Drugs Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2019-2024) Table 117. Novartis Main Business Table 118. Novartis Latest Developments Table 119. Eli Lilly and Company Basic Information, Acute Myeloid Leukemia Drugs Manufacturing Base, Sales Area and Its Competitors Table 120. Eli Lilly and Company Acute Myeloid Leukemia Drugs Product Portfolios and **Specifications** Table 121. Eli Lilly and Company Acute Myeloid Leukemia Drugs Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2019-2024) Table 122. Eli Lilly and Company Main Business Table 123. Eli Lilly and Company Latest Developments Table 124. Otsuka Holdings Basic Information, Acute Myeloid Leukemia Drugs Manufacturing Base, Sales Area and Its Competitors Table 125. Otsuka Holdings Acute Myeloid Leukemia Drugs Product Portfolios and **Specifications** Table 126. Otsuka Holdings Acute Myeloid Leukemia Drugs Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2019-2024) Table 127. Otsuka Holdings Main Business Table 128. Otsuka Holdings Latest Developments Table 129. Takeda Pharmaceuticals Basic Information, Acute Myeloid Leukemia Drugs Manufacturing Base, Sales Area and Its Competitors Table 130. Takeda Pharmaceuticals Acute Myeloid Leukemia Drugs Product Portfolios and Specifications Table 131. Takeda Pharmaceuticals Acute Myeloid Leukemia Drugs Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2019-2024) Table 132. Takeda Pharmaceuticals Main Business Table 133. Takeda Pharmaceuticals Latest Developments



List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Acute Myeloid Leukemia Drugs
- Figure 2. Acute Myeloid Leukemia Drugs Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Acute Myeloid Leukemia Drugs Sales Growth Rate 2019-2030 (K Units)
- Figure 7. Global Acute Myeloid Leukemia Drugs Revenue Growth Rate 2019-2030 (\$ Millions)
- Figure 8. Acute Myeloid Leukemia Drugs Sales by Region (2019, 2023 & 2030) & (\$ Millions)
- Figure 9. Product Picture of Chemotherapy
- Figure 10. Product Picture of Targeted Therapy
- Figure 11. Product Picture of Other
- Figure 12. Global Acute Myeloid Leukemia Drugs Sales Market Share by Type in 2023
- Figure 13. Global Acute Myeloid Leukemia Drugs Revenue Market Share by Type (2019-2024)
- Figure 14. Acute Myeloid Leukemia Drugs Consumed in Hospital
- Figure 15. Global Acute Myeloid Leukemia Drugs Market: Hospital (2019-2024) & (K Units)
- Figure 16. Acute Myeloid Leukemia Drugs Consumed in Clinic
- Figure 17. Global Acute Myeloid Leukemia Drugs Market: Clinic (2019-2024) & (K Units)
- Figure 18. Acute Myeloid Leukemia Drugs Consumed in Others
- Figure 19. Global Acute Myeloid Leukemia Drugs Market: Others (2019-2024) & (K Units)
- Figure 20. Global Acute Myeloid Leukemia Drugs Sales Market Share by Application (2023)
- Figure 21. Global Acute Myeloid Leukemia Drugs Revenue Market Share by Application in 2023
- Figure 22. Acute Myeloid Leukemia Drugs Sales Market by Company in 2023 (K Units)
- Figure 23. Global Acute Myeloid Leukemia Drugs Sales Market Share by Company in 2023
- Figure 24. Acute Myeloid Leukemia Drugs Revenue Market by Company in 2023 (\$ Million)
- Figure 25. Global Acute Myeloid Leukemia Drugs Revenue Market Share by Company



in 2023

Figure 26. Global Acute Myeloid Leukemia Drugs Sales Market Share by Geographic Region (2019-2024)

Figure 27. Global Acute Myeloid Leukemia Drugs Revenue Market Share by Geographic Region in 2023

Figure 28. Americas Acute Myeloid Leukemia Drugs Sales 2019-2024 (K Units)

Figure 29. Americas Acute Myeloid Leukemia Drugs Revenue 2019-2024 (\$ Millions)

Figure 30. APAC Acute Myeloid Leukemia Drugs Sales 2019-2024 (K Units)

Figure 31. APAC Acute Myeloid Leukemia Drugs Revenue 2019-2024 (\$ Millions)

Figure 32. Europe Acute Myeloid Leukemia Drugs Sales 2019-2024 (K Units)

Figure 33. Europe Acute Myeloid Leukemia Drugs Revenue 2019-2024 (\$ Millions)

Figure 34. Middle East & Africa Acute Myeloid Leukemia Drugs Sales 2019-2024 (K Units)

Figure 35. Middle East & Africa Acute Myeloid Leukemia Drugs Revenue 2019-2024 (\$ Millions)

Figure 36. Americas Acute Myeloid Leukemia Drugs Sales Market Share by Country in 2023

Figure 37. Americas Acute Myeloid Leukemia Drugs Revenue Market Share by Country in 2023

Figure 38. Americas Acute Myeloid Leukemia Drugs Sales Market Share by Type (2019-2024)

Figure 39. Americas Acute Myeloid Leukemia Drugs Sales Market Share by Application (2019-2024)

Figure 40. United States Acute Myeloid Leukemia Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 41. Canada Acute Myeloid Leukemia Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 42. Mexico Acute Myeloid Leukemia Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 43. Brazil Acute Myeloid Leukemia Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 44. APAC Acute Myeloid Leukemia Drugs Sales Market Share by Region in 2023

Figure 45. APAC Acute Myeloid Leukemia Drugs Revenue Market Share by Regions in 2023

Figure 46. APAC Acute Myeloid Leukemia Drugs Sales Market Share by Type (2019-2024)

Figure 47. APAC Acute Myeloid Leukemia Drugs Sales Market Share by Application (2019-2024)



Figure 48. China Acute Myeloid Leukemia Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 49. Japan Acute Myeloid Leukemia Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 50. South Korea Acute Myeloid Leukemia Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 51. Southeast Asia Acute Myeloid Leukemia Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 52. India Acute Myeloid Leukemia Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 53. Australia Acute Myeloid Leukemia Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 54. China Taiwan Acute Myeloid Leukemia Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 55. Europe Acute Myeloid Leukemia Drugs Sales Market Share by Country in 2023

Figure 56. Europe Acute Myeloid Leukemia Drugs Revenue Market Share by Country in 2023

Figure 57. Europe Acute Myeloid Leukemia Drugs Sales Market Share by Type (2019-2024)

Figure 58. Europe Acute Myeloid Leukemia Drugs Sales Market Share by Application (2019-2024)

Figure 59. Germany Acute Myeloid Leukemia Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 60. France Acute Myeloid Leukemia Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 61. UK Acute Myeloid Leukemia Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 62. Italy Acute Myeloid Leukemia Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 63. Russia Acute Myeloid Leukemia Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 64. Middle East & Africa Acute Myeloid Leukemia Drugs Sales Market Share by Country in 2023

Figure 65. Middle East & Africa Acute Myeloid Leukemia Drugs Revenue Market Share by Country in 2023

Figure 66. Middle East & Africa Acute Myeloid Leukemia Drugs Sales Market Share by Type (2019-2024)

Figure 67. Middle East & Africa Acute Myeloid Leukemia Drugs Sales Market Share by Application (2019-2024)

Figure 68. Egypt Acute Myeloid Leukemia Drugs Revenue Growth 2019-2024 (\$



Millions)

Figure 69. South Africa Acute Myeloid Leukemia Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 70. Israel Acute Myeloid Leukemia Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 71. Turkey Acute Myeloid Leukemia Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 72. GCC Country Acute Myeloid Leukemia Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 73. Manufacturing Cost Structure Analysis of Acute Myeloid Leukemia Drugs in 2023

Figure 74. Manufacturing Process Analysis of Acute Myeloid Leukemia Drugs

Figure 75. Industry Chain Structure of Acute Myeloid Leukemia Drugs

Figure 76. Channels of Distribution

Figure 77. Global Acute Myeloid Leukemia Drugs Sales Market Forecast by Region (2025-2030)

Figure 78. Global Acute Myeloid Leukemia Drugs Revenue Market Share Forecast by Region (2025-2030)

Figure 79. Global Acute Myeloid Leukemia Drugs Sales Market Share Forecast by Type (2025-2030)

Figure 80. Global Acute Myeloid Leukemia Drugs Revenue Market Share Forecast by Type (2025-2030)

Figure 81. Global Acute Myeloid Leukemia Drugs Sales Market Share Forecast by Application (2025-2030)

Figure 82. Global Acute Myeloid Leukemia Drugs Revenue Market Share Forecast by Application (2025-2030)



I would like to order

Product name: Global Acute Myeloid Leukemia Drugs Market Growth 2024-2030 Product link: <u>https://marketpublishers.com/r/G79B5AC086BEN.html</u>

> Price: US\$ 3,660.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: <u>info@marketpublishers.com</u>

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/G79B5AC086BEN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970